References
- Katsigianni M, Karageorgiou V, Lambrinoudaki I, et al. Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2019;1(12):1787–1797.
- Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24(6):834–846.
- Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. 2017;232:R99–r113.
- Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract. 2015;21(11):603–611.
- Meier RK. Polycystic Ovary Syndrome. Nurs Clin North Am. 2018;53(3):407–420.
- Yang H, Kim HJ, Pyun BJ, et al. Licorice ethanol extract improves symptoms of polycystic ovary syndrome in Letrozole-induced female rats. Integr Med Res. 2018;7(3):264–270.
- Shim HY, Park JH, Paik HD, et al. Genistein-induced apoptosis of human breast cancer MCF-7 cells involves calpain-caspase and apoptosis signaling kinase 1-p38 mitogen-activated protein kinase activation cascades. Anticancer Drugs. 2007;18(6):649–657.
- Velentzis LS, Woodside JV, Cantwell MM, et al. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer. 2008;44(13):1799–1806.
- JH W. [Research progress of soybean isoflavones]. Modern Chinese Medicine Research and Practice. 2013;27:85–88.
- Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 2004;6(3):119–127.
- Kao YC, Zhou C, Sherman M, et al. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect. 1998;106(2):85–92.
- Romualdi D, Costantini B, Campagna G, et al. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. Fertil Steril. 2008;90(5):1826–1833.
- Jamilian M, Asemi Z. The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2016;101(9):3386–3394.
- RK R, SS M, Balaji B. Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. Pharm Biol. 2017;55(1):242–251.
- Sahin I, Bilir B, Ali S, et al. Soy Isoflavones in Integrative Oncology: increased Efficacy and Decreased Toxicity of Cancer Therapy. Integr Cancer Ther. 2019;18:1534735419835310.
- Karateke A, Dokuyucu R, Dogan H, et al. Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model. Med Princ Pract. 2018;27(6):515–522.
- Wang MX, Yin Q, Xu X, et al. Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet. Med Sci Monit. 2020;26:e922136.
- LL F. Study on mRNA/lncRNA expression profile and related function in ovary of animal model of polycystic ovary syndrome. Jilin University. 2018. https://kns.cnki.net/kcms/detail/detail.aspx?FileName=1018217106.nh&DbName=CDFD2018
- Jungbauer A, Medjakovic S. Phytoestrogens and the metabolic syndrome. J Steroid Biochem Mol Biol. 2014;139:277–289.
- Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36.
- Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30–41.
- McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54–64.
- Yang S, Lv Q, Luo T, et al. Metformin inhibits expression and secretion of PEDF in adipocyte and hepatocyte via promoting AMPK phosphorylation. Mediators Inflamm. 2013;2013:429207.
- Wang Z, YH S. Polycystic ovary syndrome and chronic inflammatory cytokines. Journal of Applied Obstetrics and Gynecology. 2014;30:339–341.
- Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453–2455.
- Endocrinology Subgroup and Expert Panel CSoOaG, Chinese Medical Association. Guidelines for diagnosis and treatment of polycystic ovary syndrome in China. Chinese Journal of Obstetrics and Gynecology. 2018; 2018: 2–6
- Yan XM, Liu KL, Gao XY, et al. Intervention effects of different doses of soybean isoflavones on rats with polycystic ovary syndrome. Journal of practical Obstetrics and Gynecology. 2020;36. 626–630.
- Barnes RB, Rosenfield RL, Burstein S, et al. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989;320(9):559–565.
- Casper RF, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol. 2011;54(4):559–565.
- Wang HS, Ruan XY, Li YL. al e. Study on the relationship between malondialdehyde, retinol and the pathogenesis of polycystic ovary syndrome. Journal of Capital Medical University. 2018;39:512–516.
- Ma N, Zhou Z, Tu ZH, et al. Correlation analysis of obesity and lean PCOS with enzymes and endocrine metabolism indexes. China Women and Children’s Health Care. 2017;32. 4093–4095.
- Liu Y, XL G, Ding Y, et al. Research progress on the correlation between polycystic ovary syndrome and oxidative stress. Chinese Journal of Reproduction and Contraception. 2019;39. 79–82.
- Yuan Q, Zhang X, Liu Z, et al. Ethanol extract of Adiantum capillus-veneris L. suppresses the production of inflammatory mediators by inhibiting NF-κB activation. J Ethnopharmacol. 2013;147(3):603–611.